Merck slips on mixed news
No clear negative catalyst here, the licensing deal and analyst notes read neutral to positive, so this looks like profit-taking or technical selling within a mildly weak healthcare tape, and we will keep monitoring.
Sources: https://pharma.economictimes.indiatimes.com/amp/news/pharma-industry/merck-licenses-scibrunch-cancer-drug-in-deal-worth-up-to-2-13-bi
Sources
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works